ClinicalTrials.gg
CompletedNCT00555451Updated May 13, 2010

Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

A Phase 1 interventional study of HE3286 in Insulin Resistance, sponsored by Harbor Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-05-13.

Sponsored by Harbor Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 150 under way, 2 of them phase 3. Insulin Resistance · United States.

Planned enrollment
248th of 936
66 · median 37
Started
2007
with 61 others
Phase 1
116 of 1,118
14 open now
Registered
207th of 1,118
by date

Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 248th largest by planned enrollment of the 936 interventional ones that give a count, is one of 62 that started in 2007, is one of 116 in phase 1, and was the 207th registered.

Insulin Resistance

2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 242 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 156 (64%) stop at 75 or younger; 30 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,118 studies in Insulin Resistance with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with type II diabetes mellitus will be treated at 10 mg (5 mg BID).

Read the detailed description

HE3286 has a potentially new mechanism of action that may improve the current therapeutic options available to patients with metabolic disorders, inflammatory and autoimmune diseases. In preclinical experiments, HE3286 has shown to have anti-inflammatory activity associated with corticosteroids but without the side effects known with corticosteroid use, such as immune suppression and bone loss. HE3286 has demonstrated glucose-lowering and insulin-enhancing effects in several preclinical mouse and rat models of insulin resistance. In these experiments, HE3286 lowered blood glucose levels and prevented progression of hyperglycemia and HE3286 appeared to enhance insulin sensitivity.

03

Conditions studied

  • Insulin Resistance

Keywords

  • phase I
  • safety
  • tolerance
  • insulin resistance
  • obese
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Males or females between 18 and 65 years of age
  • for females between 29 and 35 kg/m2 and no more than 37 kgm2 for males
  • Fasting blood glucose level \< 126 mg/dL at screening
  • 2 hour postprandial (following 75 grams glucose) blood glucose between 140 to 200 mg/dL
  • Normal thyroid stimulating hormone with or without thyroid replacement therapy
  • Fasting triglycerides \< 350 mg/dL
  • For females of , agree to avoid pregnancy during the study and for 3 months following study completion, have a negative serum and/or urine pregnancy test, and use an acceptable method of
  • Non-smoker or has not smoked for 6 months prior to the screening visit
  • No history of alcohol abuse within 2 years
  • Negative drug screen at screening and baseline
  • Stable weight (+/- 5%); no history of weight loss or gain (> 10% body weight)
  • Must provide voluntary, written, prior to screening evaluations
  • Must be able to swallow capsules

Main Exclusion Criteria:

  • Marked prolongation of /QTc interval or history of additional risk factors for Torsades de Pointes at screening or baseline
  • Positive for , HAV, or
  • History of cardiovascular, hepatic, respiratory or renal or endocrine disorders
  • History of breast and/or prostate cancer
  • Clinically significant neurological or psychiatric condition, uncontrolled hypertension, clinically significant unstable medical abnormality, chronic disease or active, serious clinical infection or condition
  • Personal or family member with breast and/or prostate cancer
  • within past 5 years except for successfully treated basal cell carcinoma of the skin
  • Personal and/or family history of venous thromboembolism
  • History of stroke and/or heart attack
  • Medication prohibited from study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Interventions

  • DrugHE3286

    Dose escalating cohort driven study. 6 planned cohorts. 1. HE3286 5 mg or placebo QD for 28 days; 2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days 3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days 4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days 5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days 6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)

06

What researchers measure

Primary outcomes

  1. safety and pharmacokinetics

    Time frame: Duration of the study

Secondary outcomes

  1. To assess the potential activity of HE3286 to decrease insulin resistance

    Time frame: duration of study

07

Study locations

2 sites
  • Baton Rouge, Louisiana 70808, United States
  • dgd Research, Inc.
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2007
First posted
Nov 8, 2007
Start
Oct 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Last update
May 13, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00555451
Lead sponsor
Harbor Therapeutics
First posted
Nov 8, 2007
Start date
Oct 2007
Primary completion
Sep 2009
Completion
Sep 2009
Last update
May 13, 2010

Study contacts

Dwight R. Stickney, MD
study director · Harbor Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion